KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $81.9 million.

  • Recursion Pharmaceuticals' Accumulated Expenses rose 30.80% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year increase of 30.80%. This contributed to the annual value of $81.9 million for FY2024, which is 75.56% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Accumulated Expenses stood at $81.9 million for FY2024, which was up 75.56% from $46.6 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Accumulated Expenses peaked at $81.9 million during FY2024, and registered a low of $10.5 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $46.6 million (2023), whereas its average is $53.8 million.
  • Data for Recursion Pharmaceuticals' Accumulated Expenses shows a peak YoY spiked of 208.37% (in 2021) over the last 5 years.
  • Recursion Pharmaceuticals' Accumulated Expenses (Yearly) stood at $10.5 million in 2020, then skyrocketed by 208.37% to $32.3 million in 2021, then rose by 1.77% to $32.9 million in 2022, then spiked by 41.73% to $46.6 million in 2023, then surged by 75.56% to $81.9 million in 2024.